Compare STBA & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | ZLAB |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1995 | 2017 |
| Metric | STBA | ZLAB |
|---|---|---|
| Price | $50.79 | $20.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $43.00 | ★ $49.60 |
| AVG Volume (30 Days) | 259.8K | ★ 851.8K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 2.35 | ★ 38.46 |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $10.20 | $9.75 |
| Revenue Next Year | $4.14 | $26.03 |
| P/E Ratio | $54.04 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $34.01 | $15.96 |
| 52 Week High | $51.01 | $41.20 |
| Indicator | STBA | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 63.50 |
| Support Level | $42.52 | $16.84 |
| Resistance Level | N/A | $21.33 |
| Average True Range (ATR) | 1.00 | 0.84 |
| MACD | -0.02 | 0.19 |
| Stochastic Oscillator | 92.28 | 93.46 |
S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.